A detailed history of Simplex Trading, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 56,961 shares of IMVT stock, worth $1.57 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
56,961
Previous 24,989 127.94%
Holding current value
$1.57 Million
Previous $807,000 86.25%
% of portfolio
0.05%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$25.1 - $31.61 $802,497 - $1.01 Million
31,972 Added 127.94%
56,961 $1.5 Million
Q1 2024

Apr 25, 2024

SELL
$30.27 - $43.79 $1.59 Million - $2.3 Million
-52,493 Reduced 67.75%
24,989 $807,000
Q4 2023

Feb 02, 2024

SELL
$31.31 - $44.19 $1.49 Million - $2.11 Million
-47,730 Reduced 38.12%
77,482 $3.26 Million
Q3 2023

Nov 01, 2023

BUY
$18.55 - $39.96 $1.94 Million - $4.18 Million
104,706 Added 510.61%
125,212 $4.81 Million
Q2 2023

Aug 04, 2023

BUY
$14.2 - $23.75 $66,058 - $110,485
4,652 Added 29.34%
20,506 $388,000
Q1 2023

Apr 27, 2023

BUY
$15.27 - $19.72 $112,417 - $145,178
7,362 Added 86.69%
15,854 $245,000
Q4 2022

Feb 02, 2023

SELL
$6.59 - $17.75 $7,150 - $19,258
-1,085 Reduced 11.33%
8,492 $150,000
Q3 2022

Nov 04, 2022

BUY
$3.93 - $6.37 $37,421 - $60,655
9,522 Added 17312.73%
9,577 $53,000
Q2 2022

Aug 03, 2022

BUY
$3.38 - $5.65 $185 - $310
55 New
55 $0
Q1 2022

May 02, 2022

SELL
$5.06 - $8.77 $20,336 - $35,246
-4,019 Closed
0 $0
Q4 2021

Feb 23, 2022

SELL
$7.33 - $9.32 $49,704 - $63,198
-6,781 Reduced 62.79%
4,019 $34,000
Q3 2021

Oct 28, 2021

BUY
$7.01 - $11.37 $44,134 - $71,585
6,296 Added 139.79%
10,800 $122,000
Q2 2021

Aug 12, 2021

BUY
$9.4 - $16.85 $42,337 - $75,892
4,504 New
4,504 $47,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.